In response to feedback received from stakeholders on the company’s 2013 CR Performance Report, the 2014 CR Performance Report offers additional historical data and further consolidation of CR information, as well as an enhanced narrative to provide context for Novartis CR reporting.
I’m a cancer biologist at the Genomics Institute of the Novartis Research Foundation, and I adore my work. I love trying to figure out kinks in cancer cells that we can manipulate for drug discovery. I love studying and trying to unravel molecular pathways. I love those moments, after many failed theories and inexplicable results, when you say ‘eureka!’ and all the pieces fall into place.